Efficacy and safety of erlotinib as monotherapy for advanced non-small cell lung cancer

Acta Academiae Medicinae Sinicae

Volumn 32, Issue 2, 2010, Pages 151-156

  Wang, Meng Zhao ^a   Zhang, Xiao Tong ^a   Zhang, Xin Yong ^b   Zhang, Li ^a   Zhong, Wei ^a   Xu, Li Yan ^b   Li, Long Yun ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Epidermal growth factor receptor gene mutation; Erlotinib; Non small cell lung cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB;

ADULT; ADVANCED CANCER; ANOREXIA; ARTICLE; CLINICAL ARTICLE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENE MUTATION; HUMAN; HYPERTRANSAMINASEMIA; LUNG NON SMALL CELL CANCER; MALE; MONOTHERAPY; NAUSEA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RASH; TREATMENT RESPONSE; VOMITING;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CHI-SQUARE DISTRIBUTION; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; QUINAZOLINES; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 77952816416     PISSN: 1000503X     EISSN: None     Source Type: Journal    
DOI: 10.3881/j.issn.1000-503X.2010.02.005     Document Type: Article

References (12)

1. Haura EB. Treatment of advanced non-small-cell lung cancer; a review of current randomized clinical trials and an examination of emerging therapies [J]. Cancer Control, 2001, 8(4):326-336.
2. Bai H, Zhao J, Wand SH, et al. The detection by DHPLC of EGFR mutation in tissue and peripheral blood from patients with advanced non-small cell lung cancer [J]. Chin J Tuberc Respir Dis, 2008, 31(12):891-896.
3. Clark GM, Zborowski DM, Santabarbara P, et al. National Cancer Institute of Canada Clinical Trials Group. Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group Study BR. 21 [J]. Clin Lung Cancer, 2006, 7(6):389-394.
4. Spigel DR, Lin M, O'Neill V, et al. Final survival and safety results from a multicenter, open-label, phase 3b trial of erlotinib in patients with advanced non-small cell lung cancer [J]. Cancer, 2008, 112(12):2749-2755.
5. Wheatley-Price P, Ding K, Seymour L, et al. Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR. 21 [J]. J Clin Oncol, 2008, 26(14): 2350-2357. (Pubitemid 351787301)
6. Wacker B, Nagrani T, Weinberg J, et al. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies [J]. Clin Cancer Res, 2007, 13(13):3913-3921. (Pubitemid 47037599)
7. Gridelli C, Maione P, Amoroso D, et al. Clinical significance and treatment of skin rash from erlotinib in non-small cell lung cancer patients: results of an Experts Panel Meeting [J]. Crit Rev Oncol Hematol, 2008, 66 (2):155-162.
8. Florescu M, Hasan B, Seymour L, et al. A clinical prognostic index for patients treated with erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR. 21 [J]. J Thorac Oncol, 2008, 3 (6):590-598. (Pubitemid 351787301)
9. Cedrés S, Prat A, Martínez P, et al. Clinical surrogate markers of survival in advanced non-small cell lung cancer (NSCLC) patients treated with second-third line erlotinib [J]. Lung Cancer, 2009, 66 (2):257-261.
10. Bezjak A, Tu D, Seymour L, et al. Symptom improvement in lung cancer patients treated with erlotinib; quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR. 21 [J]. J Clin Oncol, 2006, 24 (24):3831-3837. (Pubitemid 46630729)
11. Zhu CQ, da Cunha Santos G, Ding K, et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR. 21 [J]. J Clin Oncol, 2008, 26 (26): 4268-4275. (Pubitemid 351787301)
12. Sakurada A, Tsao MS. Predictive biomarkers for EGFR therapy [J]. Idrugs, 2009, 12 (1):34-38.